Search for a clinical trial
Other search option(s)
19 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Very low doses of Rituximab for off-label treatment - a Pilot Trial (Phase 2)
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Cardinal Study: A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
A Phase 2, Open-Label Study of Parsaclisib in Participants With Autoimmune Hemolytic Anemia - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
WIEN
Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study
Allgemeines Krankenhaus der Stadt Wien
Universitätsklinik für klinische Pharmakologie
AUSTRIA
WIEN
WIEN
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion - AT
Allgemeines Krankenhaus der Stadt Wien
Universitätsklinik für klinische Pharmakologie
BELGIUM
VLAAMS BRABANT
LEUVEN
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion - BE
UZ Leuven - Campus Gasthuisberg
Department of Hematology
BELGIUM
VLAAMS BRABANT
LEUVEN
Cardinal Study: A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion - AT
UZ Leuven - Campus Gasthuisberg
Department of Hematology
GERMANY
Baden-Württemberg
ULM
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion -DE-
DRK Baden-Württemberg/ Hessen
Institut für Klinische Transfusionsmedizin und Immungenetik Ulm
GERMANY
Baden-Württemberg
ULM
Cardinal study: A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion -DE-
DRK Baden-Württemberg/ Hessen
Institut für Klinische Transfusionsmedizin und Immungenetik Ulm
GERMANY
Nordrhein-Westfalen
ESSEN
Cardinal study: A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion -DE-
Universitätsklinikum Essen
GERMANY
Nordrhein-Westfalen
ESSEN
DECADE Trial: Therapy for Chronic Cold Agglutinin Disease: A prospective, non-randomized multicentre phase II study demonstrating the efficacy of terminal complement inhibition in patients with Cold Agglutinin Disease using Eculizumab
Westdeutsches Tumorzentrum Essen (WTZ)
Klinik für Hämatologie
GERMANY
Nordrhein-Westfalen
ESSEN
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion -DE-
Westdeutsches Tumorzentrum Essen (WTZ)
Klinik für Hämatologie
SPAIN
Andalucía
SEVILLA
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of BIVV009 in patients with primary cold agglutinin disease without a recent history of blood transfusion (Phase III) - ES
Hospital Universitario Virgen del Rocío
Unidad de Hematología
SPAIN
Cataluña
BARCELONA
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of BIVV009 in patients with primary cold agglutinin disease without a recent history of blood transfusion (Phase III) - ES
Hospital Clínic de Barcelona
Servicio de Hemoterapia y Hemostasia
SPAIN
Comunidad Valenciana
VALENCIA
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of BIVV009 in patients with primary cold agglutinin disease without a recent history of blood transfusion (Phase III) - ES
Hospital Universitario Doctor Peset
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MAJADAHONDA
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of BIVV009 in patients with primary cold agglutinin disease without a recent history of blood transfusion (Phase III) - ES
Hospital Universitario Puerta de Hierro - Majadahonda
Servicio de Hematología y Hemoterapia
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion - CH
Institution: Information not provided - CH
UNITED KINGDOM
West Yorkshire
LEEDS
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion-GB
St James's University Hospital
The Leeds Teaching Hospitals NHS Trust HQ
UNITED KINGDOM
West Yorkshire
LEEDS